Figure 2.

Kaplan–Meier survival curves showing: (A) high- and low-risk subgroups identified by the AJCC staging system, our baseline model (B, D), or the mGPS (C). In the overall internal cohort (n = 203), the AJCC staging system (A) was compared to our baseline model (B). In a subgroup where albumin was available (n = 155) the mGPS (C) was compared to our baseline model (D). Experiments show representatives of a 10 × 2 cross-validation.

AJCC, American Joint Committee on Cancer; mGPS, modified Glasgow Prognostic Score.